5:42 PM
 | 
Mar 18, 2013
 |  BC Extra  |  Clinical News

Novo Nordisk falls on liraglutide data

Novo Nordisk A/S (CSE:NVO; NYSE:NVO) was off DKK39 to DKK960 on Monday and fell $8.43 to $166.45 on NYSE after announcing Phase IIIa data for liraglutide to treat obesity in Type II diabetics. Once-daily 1.8 and 3 mg doses of subcutaneous liraglutide met the SCALE Diabetes trial's three co-primary endpoints, but...

Read the full 236 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >